TY - JOUR
T1 - PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma
AU - Lo, Andrea C.
AU - James, Lyndon P.
AU - Prica, Anca
AU - Raymakers, Adam
AU - Peacock, Stuart
AU - Qu, Melody
AU - Louie, Alex V.
AU - Savage, Kerry J.
AU - Sehn, Laurie H.
AU - Hodgson, David
AU - Yang, Joanna C.
AU - Eich, Hans T.T.
AU - Wirth, Andrew
AU - Hunink, M. G.Myriam
N1 - Funding Information:
Stuart Peacock is the Academic Representative Member of the Board of Directors for the Canadian Agency for Drugs and Technologies in Health. Alex Louie has received honoraria from Astra-Zenca, RefleXion, and Varian Medical Systems. Kerry Savage has received institutional research funding from Roche. Laurie Sehn has a consultancy and has received honoraria from Incyte, Gilead, Kite, Janssen, Celgene, Acerta, Genentech, Inc., AstraZeneca, Apo-biologix, AbbVie, Amgen, Karyopharm, Lundbeck, Merck, Mor-phoSys, F. Hoffmann-La Roche Ltd., Seattle Genetics, Teva, Servier, Takeda, Chugai, TG Therapeutics, and Verastem Oncology and has received research funding from Genentech, Inc., F. Hoffmann-LaRoche Ltd., and Teva. David Hodgson is the medical director of the Pediatric Oncology Group of Ontario. M.G. Myriam Hunink receives (or received) royalties from Cambridge University Press for a textbook on medical decision making, reimbursement of expenses from the European Society of Radiology (ESR) for work on the ESR guidelines for imaging referrals, reimbursement of expenses from the European Institute for Biomedical Imaging Research for membership on the Scientific Advisory Board, and research funding from the American Diabetes Association, The Netherlands Organization for Health Research and Development, the German Innovation Fund, Netherlands Educational Grant (“Studie Voor-schot Middelen”), and the Gordon and Betty Moore Foundation. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental cost-effectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Patients with early-stage FL should undergo PET/CT before curative-intent RT.
AB - The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental cost-effectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Patients with early-stage FL should undergo PET/CT before curative-intent RT.
KW - Cost-effectiveness analysis
KW - Follicular lymphoma
KW - PET/CT
KW - Radiation therapy
KW - Staging
UR - http://www.scopus.com/inward/record.url?scp=85128118305&partnerID=8YFLogxK
U2 - 10.2967/jnumed.121.262324
DO - 10.2967/jnumed.121.262324
M3 - Article
C2 - 34413148
AN - SCOPUS:85128118305
SN - 0161-5505
VL - 63
SP - 543
EP - 548
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 4
ER -